Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AGILE THERAPEUTICS INC (AGRX)
|
Add to portfolio |
|
|
|
| Price: |
$1.87
| | Metrics |
| OS: |
1.93
|
M
| |
|
|
| Market cap: |
$3.6
|
M
| |
|
|
|
Net cash:
|
$2.28
|
M
| |
$1.19
|
per share
|
|
EV:
|
$1.32
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($36.9)
|
M
| |
|
|
|
EBIT
|
($37.4)
|
M
| |
|
|
| EPS |
($7.75)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.9 | 4.1 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 165.4% | 447.5% | | | | | | |
| Cost of goods sold | 6.8 | 10.7 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 4.0 | -6.6 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 37.2% | -161.4% | 62.3% | | | | | |
| Sales and marketing | 30.4 | 43.4 | 23.3 | 1.1 | 0.9 | | | |
| Research and development | 3.3 | 6.2 | 13.5 | 9.9 | 9.8 | 14.4 | 20.9 | 25.6 |
| General and administrative | 11.9 | 14.7 | 12.7 | 7.9 | 7.8 | 12.4 | 8.8 | 7.5 |
| EBITA | -52.3 | -70.8 | -48.9 | -18.7 | -18.5 | -26.8 | -29.7 | -33.1 |
| EBITA margin | -480.5% | -1727.5% | -6526.3% | | | | | |
| Amortization of intangibles | 0.3 | 0.2 | 0.2 | 0.1 | | | | |
| EBIT | -52.6 | -71.0 | -49.1 | -18.9 | -18.5 | -26.8 | -29.7 | -33.1 |
| EBIT margin | -482.9% | -1731.4% | -6549.1% | | | | | |
| Pre-tax income | -30.1 | -71.1 | -51.9 | -18.6 | -20.3 | -28.3 | -31.8 | -36.3 |
| Income taxes | -4.7 | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | -3.1 | -6.0 |
| Tax rate | 15.5% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% | 9.7% | 16.4% |
| Net income | -25.4 | -71.1 | -51.9 | -18.6 | -19.8 | -28.3 | -28.7 | -30.3 |
| Net margin | -233.5% | -1732.9% | -6923.0% | | | | | |
| |
| Diluted EPS | ($1.18) | ($29.28) | ($24.49) | ($0.38) | ($0.58) | ($0.91) | ($1.02) | ($1.38) |
| Shares outstanding (diluted) | 21.6 | 2.4 | 2.1 | 49.4 | 34.3 | 30.9 | 28.3 | 22.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|